Lisinopril congestive heart failure
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Lisinopril in the Treatment of Congestive Heart Failure
Introduction to Lisinopril and Congestive Heart Failure
Lisinopril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, has been extensively studied for its efficacy in treating congestive heart failure (CHF). CHF is a condition where the heart is unable to pump blood effectively, leading to symptoms such as fatigue, shortness of breath, and fluid retention. This article synthesizes findings from multiple studies to provide a comprehensive overview of the role of lisinopril in managing CHF.
Efficacy of Lisinopril in Improving Exercise Tolerance
Several studies have demonstrated that lisinopril significantly improves exercise tolerance in patients with CHF. In a randomized, double-blind study comparing lisinopril to captopril, patients receiving lisinopril showed a greater increase in exercise duration on a treadmill . Another study confirmed that lisinopril treatment led to significant improvements in both bicycle and treadmill exercise tolerance. These improvements were consistent across different age groups, including patients over 65 years old.
Impact on Cardiac Function and Symptoms
Lisinopril has been shown to enhance cardiac function and alleviate symptoms of CHF. In a multicenter study, lisinopril significantly improved left ventricular ejection fraction (LVEF) and reduced the cardiothoracic ratio and echocardiographic end-systolic diameter. Additionally, patients treated with lisinopril experienced significant improvements in clinical signs and symptoms of heart failure, such as reduced dyspnea and fatigue .
Comparison with Other ACE Inhibitors
When compared to captopril, another ACE inhibitor, lisinopril demonstrated superior efficacy in certain aspects. Patients with renal impairment showed better exercise tolerance improvements with lisinopril than with captopril . Moreover, lisinopril increased LVEF in patients with moderately to severely decreased function, an effect not observed with captopril . Both drugs were well tolerated, but lisinopril was found to be equally effective in patients with renal impairment, whereas captopril was not.
Safety and Tolerability
Lisinopril has been generally well tolerated in clinical trials. The incidence of adverse effects such as mild hypotension and dizziness was not significantly different from placebo . In a study involving older patients, lisinopril was found to be safe and well-tolerated, with no significant differences in adverse effects compared to captopril. However, lisinopril was associated with more frequent increases in serum creatinine, although these changes were rarely of significant consequence.
Special Populations: Patients with Atrial Fibrillation
Lisinopril has also been evaluated in patients with CHF and chronic atrial fibrillation. In a double-blind, randomized, placebo-controlled trial, lisinopril improved peak oxygen consumption and tended to lower plasma norepinephrine levels during exercise. This suggests that lisinopril may be particularly effective in this patient category due to its antiadrenergic properties.
Conclusion
Lisinopril is a potent and effective ACE inhibitor for the treatment of congestive heart failure. It improves exercise tolerance, cardiac function, and symptoms of CHF, and is well-tolerated across different patient populations. When compared to other ACE inhibitors like captopril, lisinopril shows superior efficacy in certain aspects, particularly in patients with renal impairment. These findings underscore the importance of lisinopril as a valuable therapeutic option in the management of CHF.
Sources and full results
Most relevant research papers on this topic